Sumamry WIN 55,212-2, classified as an aminoalkylindole derivative, exerts effects akin to cannabinoids such as tetrahydrocannabinol (THC) but boasts a distinctly unique chemical structure.Functionally, WIN 55,212-2 acts as a robust cannabinoid receptor agonist,[6] demonstrating potent analgesic properties in a rat model of neuropathic pain, activating p42 and p44 MAP kinase through receptor-mediated signaling.At a concentration …
Summary QMPSB, initially identified as an aryl sulfonamide-based synthetic cannabinoid, found its place in the realm of designer drugs.In 2007, Nathalie Lambeng and her research team unearthed QMPSB, unveiling its role as a robust full agonist of the CB1 and CB2 receptors, boasting impressive Ki values of 3 nM and 4 nM, respectively. Following this …
Summary NESS-040C5, designed for glaucoma treatment, is a robust cannabinoid agonist. It demonstrates a notable preference for the CB2 receptor subtype, boasting a remarkable CB2 affinity at 0.4 nanomolar and a selectivity exceeding 25-fold when compared to the closely related CB1 receptor. Identifiers IUPAC name CAS Number 1445751-90-5 PubChem CID 138402821 UNII P6H2AAY2GE CompTox Dashboard …
Summary NESS-0327 is a pharmaceutical substance utilized in scientific investigations, recognized for its remarkable role as a highly potent and exceedingly selective antagonist of the cannabinoid receptor CB1. Its antagonistic potency greatly surpasses the more commonly employed ligand, rimonabant. With an astounding Ki at CB1 measuring a mere 350 femtomolar (0.00035 nanomolar), NESS-0327 exhibits an …
Summary MDA-19 also recognized as BZO-HEXOXIZID, is a potent and highly selective agonist specifically designed for the cannabinoid receptor CB2. It maintains reasonable selectivity over the psychoactive CB1 receptor, although variations are observed among different species. In animal studies, MDA-19 has shown effectiveness in addressing neuropathic pain, with no significant impact on rat locomotor activity …
Summary LY-2183240 is a multifaceted compound known for its dual role as a robust inhibitor of both endocannabinoid anandamide reuptake and the enzyme fatty acid amide hydrolase (FAAH), responsible for anandamide degradation. This distinctive mechanism leads to a significant increase in anandamide levels within the brain, resulting in observed analgesic and anxiolytic effects in animal …
Summary JTE 7-31, a creation of Japan Tobacco, emerges as a selective agonist for cannabinoid receptors. This compound exhibits significant selectivity for CB2 receptors, yet it maintains a noteworthy affinity for CB1 receptors, boasting a Ki of 0.088nM at CB2 compared to 11nM at CB1. Identifiers CAS Number 194358-72-0 3D model (JSmol) Interactive image ChemSpider …
Summary JTE-907 is a pharmaceutical compound employed in scientific investigations, functioning as a discerning CB2 inverse agonist. This substance has demonstrated anti-inflammatory properties in animal experiments, with these effects believed to stem from an interplay between the CB2 receptor and IgE. Identifiers IUPAC name CAS Number 282089-49-0 PubChem CID 9867770 ChemSpider 8043461 UNII DAV3Q7SNOL CompTox …
Summary FUBIMINA, also recognized under the aliases BIM-2201, BZ-2201, and FTHJ, is a synthetic cannabinoid, constituting the benzimidazole counterpart to AM-2201. This compound has gained prominence as an active ingredient within synthetic cannabis blends. Its initial discovery took place in Japan in 2013, concurrently with the identification of MEPIRAPIM.FUBIMINA exerts its influence as a moderately …
Summary EG-018, a synthetic cannabinoid rooted in the carbazole structure, has found a niche in online markets as a designer drug. This compound is a partial agonist for CB1 and CB2 receptors, exhibiting a notably robust binding affinity. However, its effectiveness in eliciting a signaling response still needs to be higher. Identifiers IUPAC name CAS …
